SER - NYSE

Serina Therapeutics, Inc.

SER·NYSE

$5.00

+0.0000%

HealthcareBiotechnology

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$51.25M

EPS-0.6445

P/E Ratio-2.39

Earnings Date11/11/2025

ser

Other Non-Current Assets

Last Annual Value

0.00

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Serina Therapeutics, Inc. Competitors Analysis of Other Non-Current Assets

SER · NYSE

Company	Other Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Serina Therapeutics, Inc. NYSE:SER	0.00	N/A	N/A	N/A
Mersana Therapeutics, Inc. NASDAQ:MRSN	978.00K	27.0%	-12.2%	24.4%
Coeptis Therapeutics, Inc. NASDAQ:COEP	4.25M	199.4%	-1.4%	N/A
Estrella Immunopharma, Inc. NASDAQ:ESLA	1.50M	N/A	N/A	N/A
Fortress Biotech, Inc. NASDAQ:FBIO	1.62M	-27.7%	-13.9%	-20.6%
Karyopharm Therapeutics Inc. NASDAQ:KPTI	267.00K	-45.3%	-57.9%	-5.7%
Senti Biosciences, Inc. NASDAQ:SNTI	3.64M	21.5%	17.6%	N/A
Telomir Pharmaceuticals, Inc. Common Stock NASDAQ:TELO	0.00	N/A	N/A	N/A

Serina Therapeutics, Inc. Fair Value Envelope

SER · NYSE

Our analysis suggests that SER has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5, this represents a potential HIDDEN relative to our calculated worth for Serina Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $5

Related Guides

Blog Categories

Continue your SER research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.